ATE393625T1 - Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen - Google Patents

Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen

Info

Publication number
ATE393625T1
ATE393625T1 AT04740032T AT04740032T ATE393625T1 AT E393625 T1 ATE393625 T1 AT E393625T1 AT 04740032 T AT04740032 T AT 04740032T AT 04740032 T AT04740032 T AT 04740032T AT E393625 T1 ATE393625 T1 AT E393625T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
hydroxy tamoxifen
excessive scaring
excessive
Prior art date
Application number
AT04740032T
Other languages
English (en)
Inventor
Andrew Palumbo
Julius Few
Dana Hilt
Original Assignee
Ascend Therapeutics Inc
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascend Therapeutics Inc, Univ Northwestern filed Critical Ascend Therapeutics Inc
Application granted granted Critical
Publication of ATE393625T1 publication Critical patent/ATE393625T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04740032T 2003-06-09 2004-06-02 Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen ATE393625T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47661803P 2003-06-09 2003-06-09

Publications (1)

Publication Number Publication Date
ATE393625T1 true ATE393625T1 (de) 2008-05-15

Family

ID=33551623

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740032T ATE393625T1 (de) 2003-06-09 2004-06-02 Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen

Country Status (12)

Country Link
US (1) US7767717B2 (de)
EP (1) EP1631275B1 (de)
JP (1) JP4682129B2 (de)
AT (1) ATE393625T1 (de)
AU (1) AU2004246812B8 (de)
CA (1) CA2528431C (de)
DE (1) DE602004013439T2 (de)
DK (1) DK1631275T3 (de)
ES (1) ES2304610T3 (de)
NZ (1) NZ544031A (de)
PT (1) PT1631275E (de)
WO (1) WO2004110420A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572178B1 (de) 2002-12-18 2006-05-03 Laboratoires Besins International Behandlung von mastalgie mit4-hydroxy-tamoxifen
EP2050443B1 (de) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
CA2549824C (en) * 2003-12-15 2012-03-13 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (de) * 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.
EP2046310B1 (de) * 2006-07-31 2011-11-02 Besins Healthcare Luxembourg SARL Behandlung und prävention von übermässiger narbenbildung
EP1891945A1 (de) * 2006-07-31 2008-02-27 Laboratoires Besins International Behandlung und Prävention von übermässiger Narbenbildung
JP2011507860A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス, インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
EP2252690A2 (de) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Verwendung von anti-connexin-43-polynukleotiden zur behandlung abnormaler oder übermässiger narben
US20140350106A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same
US20140350117A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Topical Scar Treatment Composition and Method of Using Same
EP3675874B1 (de) * 2017-09-01 2023-11-29 Excel Med, LLC Pharmazeutische zusammensetzung zur behandlung von keloid und verwendungen davon
WO2022192626A1 (en) * 2021-03-11 2022-09-15 Ohio State Innovation Foundation Use of tamoxifen and related compounds to reduce breast implant capsule formation and capsular contracture

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
EP0485470B1 (de) * 1989-07-31 1994-03-16 Massachusetts Institute Of Technology Verwendung von calciumantagonisten für die behandlung von narben
TW218849B (de) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
DE69334068D1 (de) * 1992-07-20 2006-11-16 Massachusetts Inst Technology Kontrolle der wundvernarbung mit calmodulin-inhibitoren oder protein-kinase-c-inhibitoren
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
AU2513899A (en) * 1997-12-23 1999-07-19 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1317921B1 (de) * 2001-12-07 2009-08-19 Besins International Belgique Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung
EP1572178B1 (de) * 2002-12-18 2006-05-03 Laboratoires Besins International Behandlung von mastalgie mit4-hydroxy-tamoxifen
EP2050443B1 (de) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (de) 2004-03-22 2005-09-28 Laboratoires Besins International 4-Hydroxytamoxifen zur Behandlung von benignen Brusterkrankungen
EP1647271A1 (de) * 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.

Also Published As

Publication number Publication date
CA2528431A1 (en) 2004-12-23
AU2004246812B2 (en) 2009-12-17
US20050032910A1 (en) 2005-02-10
HK1082203A1 (en) 2006-06-02
JP2006527234A (ja) 2006-11-30
ES2304610T3 (es) 2008-10-16
WO2004110420A1 (en) 2004-12-23
CA2528431C (en) 2012-09-18
JP4682129B2 (ja) 2011-05-11
AU2004246812B8 (en) 2010-01-14
EP1631275B1 (de) 2008-04-30
DE602004013439D1 (de) 2008-06-12
PT1631275E (pt) 2008-08-04
DK1631275T3 (da) 2008-08-18
US7767717B2 (en) 2010-08-03
EP1631275A1 (de) 2006-03-08
DE602004013439T2 (de) 2009-06-04
WO2004110420A8 (en) 2005-11-24
AU2004246812A1 (en) 2004-12-23
NZ544031A (en) 2008-08-29

Similar Documents

Publication Publication Date Title
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
PT1631275E (pt) Tratamento e prevenção da cicatrização excessiva com 4-hidroxi-tamoxifeno
ATE316786T1 (de) Behandlung von mukositis
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
ATE460164T1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
EA200971053A1 (ru) Способы лечения кожных язв
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
BR0312597A (pt) Combinações de drogas para o tratamento de neoplasmas
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
DE60212613D1 (de) Doxycyclin zur behandlung von akne
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
DE602004011051D1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE382354T1 (de) Präoperative behandlung von postoperativen schmerzen
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
DE60335093D1 (de) Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
DE60231994D1 (de) Mittel zur behandlung oder prävention allergischerg

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1631275

Country of ref document: EP